March 22, 2021 08:34 AM EDTUpdated 08:50 AM

Those NDA plans Odonate had for mid-'21? They're being scrapped — along with the entire biotech — in a sudden implosion

John Carroll

Editor & Founder

Last summer, San Diego-based Odonate $ODT CEO Kevin Tang enthusiastically sought to bolster investors’ enthusiasm for the company with what the biotech called “a potential …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Those NDA plans Odonate had for mid-'21? They're being scrapped — along with the entire biotech — in a sudden implosion

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Those NDA plans Odonate had for mid-'21? They're be­ing scrapped — along with the en­tire biotech — in a sud­den im­plo­sion

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Those NDA plans Odonate had for mid-'21? They're being scrapped — along with the entire biotech — in a sudden implosion